Urethral Dilators Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

The Urethral Dilators Report is Segmented by Product Type (Balloon, Drug-Coated Balloon, Rigid, Hydraulic, and More), Usage (Disposable and Reusable), Application (Urethral Stricture, Meatal Stenosis, and More), End User (Hospitals, Urology Clinics, and Home Care), and Geography (North America, Europe, Asia-Pacific, MEA, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Urethral Dilators Market Size and Share

Urethral Dilators Market Size
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Urethral Dilators Market Analysis by Mordor Intelligence

The Urethral Dilators Market size is expected to grow from USD 291.34 million in 2026 to USD 308.26 million in 2027 and is forecast to reach USD 408.84 million by 2032 at 5.81% CAGR over 2027-2032.

The urethral dilators market is moving toward higher-value balloon systems while conventional rigid and sequential instruments continue to support procedure volumes. Drug-coated balloons are gaining clinical acceptance for recurrent strictures because they combine mechanical dilation with local drug delivery. This shift supports revenue growth but narrows the role of lower-priced reusable products in settings that can adopt advanced systems. Rising catheter use, endoscopic interventions, and older male populations continue to support procedure demand in the urethral dilators market. Urethroplasty remains an important alternative after failed endoscopic treatment and may reduce repeat dilation procedures for selected patients.

Key Report Takeaways

  • By product type, balloon dilators held 31.9% of the urethral dilators market share in 2026, while hydraulic urethral dilators are projected to grow at a 7.6% CAGR through 2032.
  • By usage, disposable instruments accounted for 63.0% of the urethral dilators market size in 2026 and are forecast to grow at a 7.8% CAGR through 2032.
  • By application, recurrent urethral stricture held a 33.9% revenue share in 2026, while kidney stone removal and nephrostomy tract dilation are expected to expand at a 9.0% CAGR through 2032.
  • By end user, hospitals accounted for 42.8% revenue share in 2026, while home care settings are forecast to expand at an 8.9% CAGR through 2032.
  • By geography, North America held a 42.8% revenue share in 2026, while Asia-Pacific is expected to grow at a 6.5% CAGR through 2032.

Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.

Urethral Dilators Market Segment Analysis

By Product Type:

Balloon Formats Anchor Revenue While Hydraulic Platforms Scale

Balloon dilators held a 31.9% revenue share in 2026 and remain the largest product category in the urethral dilators market. Their established role in outpatient and operating-room treatment supports broad use across urology departments, sustaining demand across the urethral dilators industry. Balloon systems are compatible with common endoscopic workflows and are supported by established clinical familiarity. Drug-Coated Balloon Dilators are smaller in current revenue but contribute strongly to value growth because they target recurrent strictures. Five-year ROBUST I data reported 71.7% freedom from reintervention, which supports clinician confidence in this approach. Hydraulic Urethral Dilators are forecast to grow at a 7.6% CAGR through 2032. Their pressure-controlled expansion supports careful treatment in complex or recurrent cases.

Rigid and sequential dilators, filiforms and followers, and metal and plastic urethral dounds continue to serve routine assessment and uncomplicated primary-stricture procedures. These formats remain useful in community practice and lower-resource settings because they are familiar and require limited supporting equipment. Their volume growth is moderated by the move toward disposable and balloon-based products. The 2026 European guidance supports drug-coated balloon treatment after repeated endoscopic management for selected recurrent bulbar strictures under 3 cm. This clinical pathway directs some higher-value procedures toward advanced balloon platforms, influencing product development and adoption across the urethral dilators industry. Laborie began the ENDURE 1 study in October 2025 to assess an Optilume ureteric drug-coated balloon for benign ureteric strictures up to 4 cm. The study indicates a potential extension of drug-coated balloon technology beyond its core urethral use.

Need more granular breakdown of segment shares?

Get tailored market insights for your requirements.

Urethral Dilators Market Share by Product Type, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Urethral Dilators Market Share by Product Type, 2026

By Usage:

Disposable Formats Lead and Accelerate Simultaneously

Disposable devices accounted for 63.0% of revenue in 2026 and are projected to grow at a 7.8% CAGR through 2032. This combination makes disposables both the leading and fastest-growing usage segment. Infection-control requirements favor single-use products across hospitals in North America and Western Europe. Growth is also becoming more visible in Asia-Pacific as hospital procurement standards advance. The U.S. Centers for Medicare & Medicaid Services introduced HCPCS codes A4295, A4296, and A4297 for hydrophilic catheters effective January 1, 2026. These codes reinforce the reimbursement infrastructure for eligible disposable catheter products. The urethral dilators market benefits when clinical safety and billing pathways support the same format.

Reusable instruments retain a meaningful role in hospitals with constrained budgets and established sterilization capacity. This is particularly relevant across parts of South Asia, Latin America, and sub-Saharan Africa. Their lower purchase cost can remain attractive where single-use procurement is difficult to fund. Reprocessing requirements, sterilant costs, and polymer-price changes can weaken their cost advantage over time. Single-use hydrophilic catheters are designed to reduce handling and support clean intermittent catheterization in home settings. Coloplast has continued to develop this product category as part of its continence-care portfolio. The balance between infection control, affordability, and reprocessing resources will continue to determine the disposable and reusable split.

By Application:

Recurrent Strictures Drive Volume, Nephrostomy Dilation Drives Growth

Recurrent urethral stricture represented 33.9% of revenue in 2026 and is the central clinical application in the urethral dilators market. Recurrent disease generates repeated treatment needs because conventional endoscopic approaches have high recurrence rates. A 2025 review cited recurrence of 60% to 90% at 2 to 5 years after endoscopic dilation. Patients who meet clinical criteria for drug-coated balloons increasingly enter a premium treatment pathway. Conventional balloon and sequential systems remain relevant in community practice and settings with limited access to advanced devices. Primary Urethral Stricture and Meatal Stenosis remain stable applications with straightforward treatment pathways. Catheter Placement and Bladder Outlet Access also supports steady use in hospital intensive-care and post-surgical settings.

Kidney stone removal and nephrostomy tract dilation is forecast to grow at a 9.0% CAGR through 2032. The application benefits from greater use of percutaneous nephrolithotomy and mini-endoscopic combined intrarenal surgery, which require tract-dilation systems. Precise, stepwise dilation supports safe access during these procedures. Cook Medical launched the Syfonix Suction Ureteral Access Sheath and a 7.5 Fr Ascend Single-Use Flexible Ureteroscope for the U.S. and Canadian stone-management market in March 2026. The launch reflects a wider focus on devices that support access, visualization, and stone treatment within one workflow. Manufacturers can strengthen their position by offering compatible access sheaths, dilators, and endoscopic products. This creates procurement opportunities across the broader interventional urology pathway.

Segment this market the way your business does.

Get tailored market insights for your requirements.

Urethral Dilators Market Share by Application, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By End User:

Hospitals Lead While Home Care Drives Faster Growth

Hospitals accounted for 42.8% of revenue in 2026 and remain the largest end-user segment. Hospital urology departments influence brand choice because they manage complex procedures and establish physician familiarity. High-volume academic centers are often early users of drug-coated balloon technology. Community hospitals continue to use conventional balloon and sequential products for routine care. Specialty Urology Clinics are gaining importance as suitable procedures move from the operating room to outpatient settings. This migration is supported by cost management, recovery protocols, and procedures that do not require general anesthesia. Hospitals therefore remain the principal qualification point for suppliers in the urethral dilators market.

Home care settings are projected to grow at an 8.9% CAGR through 2032. Older patients with long-term stricture disease increasingly manage maintenance treatment outside hospitals. However, patient-reported outcomes show that sustained self-dilation can be uncomfortable and demanding. The 121-patient study reported worsening quality-of-life scores over 48 months despite ongoing catheterization. Product design is important because handling, insertion comfort, and contamination concerns affect continued use. Closed systems, hydrophilic coatings, and no-touch sleeves respond directly to these needs. Home-care growth will depend on whether manufacturers can reduce the practical burden of self-administration for patients and caregivers.

Geography Analysis

North America

North America accounted for 42.8% of revenue in 2026 and remains the leading regional segment. The region combines high urology procedure volumes with established access to specialist care. Urethral stricture disease drives an estimated 1.5 million U.S. clinic visits and 5,000 hospital admissions each year. Reimbursement support is widening access to advanced products, especially for eligible catheter and balloon procedures. The new U.S. HCPCS codes for hydrophilic catheters took effect in January 2026. Cook Medical received a Vizient contract for its urology portfolio in September 2025, covering catheters, balloons, dilation and access devices, and ureteral stents. The contract gives the company access to a major provider-led purchasing network and reflects the importance of group purchasing arrangements in the urethral dilators market. Advanced visualization, procedural integration, and payer coverage support a premium product mix in the region.

Asia-Pacific

Asia-Pacific is projected to grow at a 6.5% CAGR through 2032, the highest regional rate in the forecast period. Japan, China, India, and South Korea provide the main sources of regional demand. Japan’s clinical practice patterns remain favorable to dilation-based management, with 94.2% of respondents in a 2025 survey reporting use of urethral dilation. Population aging raises the need for care among patients with catheter exposure, prior procedures, and other urological conditions. Hospitals in the region are also expanding their ability to perform endoscopic and interventional urology procedures. These developments create a larger base for both conventional dilators and single-use catheter-related products. Suppliers that match product launches to local reimbursement channels can improve access in the urethral dilators market. This gives the urethral dilators market a broader range of purchasing environments than mature Western systems. Product affordability and clinician training remain essential because premium drug-coated balloon adoption is still uneven across the region.

Europe, Middle East and Africa, and South America

Europe is a major revenue pool, supported by Germany, the United Kingdom, France, and the Nordic countries. German data showed urethroplasty rose 156% between 2006 and 2023, while urethral dilation declined 17%. This pattern increases the need to position drug-coated balloon treatment between routine endoscopy and open reconstruction for appropriate recurrent cases. European suppliers also face compliance requirements under the EU Medical Device Regulation 2017/745, which can favor companies with strong regulatory resources. The Middle East and Africa remain earlier-stage markets, with demand concentrated in Gulf hospitals that invest in advanced urology services. South America is mainly hospital led, with Brazil and Argentina providing substantial demand. Affordability and distributor reach are important regional considerations, particularly where local suppliers offer simpler dilator formats at lower prices. These mixed markets offer volume opportunities, while product mix and procurement conditions vary sharply by country. The urethral dilators market must therefore accommodate different product specifications and price points across these geographies.

Urethral Dilators Market Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Market Concentration

Urethral Dilators Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

The urethral dilators market is fragmented to moderately consolidated, with diversified device companies, specialty urology suppliers, and regional manufacturers all participating. Boston Scientific, Teleflex, Cook Medical, B. Braun, and Coloplast are active across conventional balloon, catheter, and access-device categories. Laborie Medical Technologies holds a differentiated position in drug-coated balloon treatment through its Optilume platform. No company share data were provided that would establish a dominant market leader. Competition is therefore based on clinical evidence, product usability, reimbursement access, sales coverage, and pricing. Larger suppliers can combine dilation products with endoscopes, catheters, access sheaths, and procedural-support technologies. This structure gives the urethral dilators market space for specialist firms that focus on a limited clinical workflow. Regional companies can compete where buyers prioritize cost and local service support.

Laborie has used clinical evidence and payer engagement to support adoption of Optilume. Its 2025 ROBUST I publication reported 71.7% freedom from reintervention at 5 years. Laborie also started the ENDURE 1 study in October 2025 to evaluate a ureteric drug-coated balloon for benign ureteric strictures. Cook Medical used contract access as another commercial lever when it received the Vizient urology contract in September 2025. In March 2026, the company added new single-use devices for stone-management procedures. These moves expand the company’s presence in adjacent urology workflows that use dilation and access products. They also allow suppliers to use established relationships when competing in the urethral dilators market.

Boston Scientific received FDA clearance for its Asurys Fluid Management System in March 2026. The system supports irrigation and distention management across ureteroscopy, cystoscopy, percutaneous nephrolithotomy, and benign prostatic hyperplasia procedures. Coloplast continues to emphasize hydrophilic and home-care catheter technologies within its longer-term continence-care strategy. Product differentiation increasingly centers on coatings, guidewire compatibility, radiopaque markers, flexible tips, and simpler handling. European compliance requirements can raise the burden for small companies that lack dedicated regulatory capacity. Suppliers that pair clinical support with reliable distribution will be best placed to compete across mature and price-sensitive markets. This competitive environment does not indicate concentration around a single supplier. The urethral dilators market still rewards both broad portfolios and narrowly focused product development.

Urethral Dilators Industry Leaders

  1. Laborie Medical Technologies Corp.

  2. Cook Medical LLC

  3. Boston Scientific Corporation

  4. Coloplast A/S

  5. Teleflex Incorporated

  6. *Disclaimer: Major Players sorted in no particular order

Urethral Dilators Market Companies Covered in this Report

  • Advin Health Care
  • B. Braun
  • Beckton Dickinson
  • Boston Scientific
  • Coloplast
  • ConvaTec Group plc
  • Cook Group
  • Karl Storz
  • Laborie
  • Laborie’s Urotronic, Inc.
  • Medi-Globe
  • MED pro Medical B.V.
  • Richard Wolf
  • Smiths Medical, an ICU Medical company
  • Teleflex
  • Urovision-Urotech, a Medi-Globe Group company
  • UROMED Kurt Drews KG
  • Well Lead Medical Co., Ltd.

Recent Industry Developments in Urethral Dilators Market

  • March 2026: Boston Scientific received FDA 510(k) clearance for the Asurys Fluid Management System, designed to manage irrigation and distention across ureteroscopy, cystoscopy, PCNL, and BPH procedures. Limited U.S. market release commenced immediately after clearance, expanding the company's integrated urology procedure ecosystem.
  • March 2026: Cook Medical commercially launched the Syfonix Suction Ureteral Access Sheath and a new 7.5 Fr Ascend Single-Use Flexible Ureteroscope for kidney stone management procedures in the United States and Canada, strengthening its single-use disposable urology portfolio.
  • October 2025: Laborie Medical Technologies announced the first procedures in its ENDURE 1 clinical study evaluating the Optilume Ureteric Drug-Coated Balloon for benign ureteric strictures up to 4 cm, initiated at the University of California Irvine Health. The study represents the first extension of the Optilume DCB platform into the ureteric indication.

Table of Contents for Urethral Dilators Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope Of The Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Urethral Strictures and Urinary Obstruction
    • 4.2.2 Shift Toward Visually Controlled and Minimally Invasive Dilation
    • 4.2.3 Expansion of Drug-Coated Balloon Treatment for Recurrent Strictures
    • 4.2.4 Aging Male Population and Catheter-Related Strictures
    • 4.2.5 National Reimbursement Pathways for Advanced Dilation Devices
    • 4.2.6 Procedure-Specific Design Improvements for Home and Outpatient Use
  • 4.3 Market Restraints
    • 4.3.1 Preference for Urethroplasty After Failed Endoscopic Treatment
    • 4.3.2 Pain, Difficult Catheterization, and Quality-of-Life Burden in Self-Dilation
    • 4.3.3 Low Physician Payment and Budget Pressure for Advanced Balloon Procedures
    • 4.3.4 Polymer, Sterilant, and Reprocessing Cost Volatility
  • 4.4 Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter's Five Forces Analysis
    • 4.7.1 Threat Of New Entrants
    • 4.7.2 Bargaining Power Of Buyers
    • 4.7.3 Bargaining Power Of Suppliers
    • 4.7.4 Threat Of Substitutes
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Product Type
    • 5.1.1 Balloon Dilators
    • 5.1.2 Drug-Coated Balloon Dilators
    • 5.1.3 Rigid and Sequential Dilators
    • 5.1.4 Hydraulic Urethral Dilators
    • 5.1.5 Filiforms and Followers
    • 5.1.6 Metal and Plastic Urethral Sounds
    • 5.1.7 Other Product Types
  • 5.2 By Usage
    • 5.2.1 Disposable
    • 5.2.2 Reusable
  • 5.3 By Application
    • 5.3.1 Recurrent Urethral Stricture
    • 5.3.2 Primary Urethral Stricture
    • 5.3.3 Meatal Stenosis
    • 5.3.4 Kidney Stone Removal and Nephrostomy Tract Dilation
    • 5.3.5 Catheter Placement and Bladder Outlet Access
    • 5.3.6 Other Applications
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Specialty Urology Clinics
    • 5.4.3 Home Care Settings
    • 5.4.4 Other End User
  • 5.5 Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles {(Includes Global Level Overview, Market Level Overview, Core Segments, Financials As Available, Strategic Information, Market Rank/Share For Key Companies, Products & Services, And Recent Developments)}
    • 6.3.1 Advin Health Care
    • 6.3.2 B. Braun Melsungen AG
    • 6.3.3 Becton, Dickinson and Company
    • 6.3.4 Boston Scientific Corporation
    • 6.3.5 Coloplast A/S
    • 6.3.6 ConvaTec Group plc
    • 6.3.7 Cook Medical LLC
    • 6.3.8 KARL STORZ SE & Co. KG
    • 6.3.9 Laborie Medical Technologies Corp.
    • 6.3.10 Laborie’s Urotronic, Inc.
    • 6.3.11 Medi-Globe GmbH
    • 6.3.12 MED pro Medical B.V.
    • 6.3.13 Richard Wolf GmbH
    • 6.3.14 Smiths Medical, an ICU Medical company
    • 6.3.15 Teleflex Incorporated
    • 6.3.16 Urovision-Urotech, a Medi-Globe Group company
    • 6.3.17 UROMED Kurt Drews KG
    • 6.3.18 Well Lead Medical Co., Ltd.

7. Market Opportunities & Future Outlook

  • 7.1 White-Space & Unmet-Need Assessment

Global Urethral Dilators Market Report Scope

According to the report’s scope, urethral dilators are medical instruments used to gently widen a narrowed urethra. They may help improve urine flow and support diagnosis or treatment of urethral strictures.

The urethral dilators market is segmented into product type, usage, application, end user, and geography. By product type, the market is segmented into balloon dilators, drug-coated balloon dilators, rigid and sequential dilators, hydraulic urethral dilators, filiforms and followers, metal and plastic urethral sounds, and other product types. By usage, the market is segmented into disposable and reusable. By application, the market is segmented into recurrent urethral stricture, primary urethral stricture, meatal stenosis, kidney stone removal and nephrostomy tract dilation, catheter placement and bladder outlet access, and other applications. By end user, the market is segmented into hospitals, specialty urology clinics, home care settings, and other end user. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers values (USD) for all the above segments.  

Segmentation Overview

By Product Type
Urethral Dilators Market segmentation breakdown
Balloon Dilators
Drug-Coated Balloon Dilators
Rigid and Sequential Dilators
Hydraulic Urethral Dilators
Filiforms and Followers
Metal and Plastic Urethral Sounds
Other Product Types
By Usage
Urethral Dilators Market segmentation breakdown
Disposable
Reusable
By Application
Urethral Dilators Market segmentation breakdown
Recurrent Urethral Stricture
Primary Urethral Stricture
Meatal Stenosis
Kidney Stone Removal and Nephrostomy Tract Dilation
Catheter Placement and Bladder Outlet Access
Other Applications
By End User
Urethral Dilators Market segmentation breakdown
Hospitals
Specialty Urology Clinics
Home Care Settings
Other End User
Geography
Urethral Dilators Market segmentation breakdown
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Urethral Dilators Market segmentation breakdown
By Product Type Balloon Dilators
Drug-Coated Balloon Dilators
Rigid and Sequential Dilators
Hydraulic Urethral Dilators
Filiforms and Followers
Metal and Plastic Urethral Sounds
Other Product Types
By Usage Disposable
Reusable
By Application Recurrent Urethral Stricture
Primary Urethral Stricture
Meatal Stenosis
Kidney Stone Removal and Nephrostomy Tract Dilation
Catheter Placement and Bladder Outlet Access
Other Applications
By End User Hospitals
Specialty Urology Clinics
Home Care Settings
Other End User
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America

Key Questions Answered in the Report

What is driving demand for urethral dilators?

Rising stricture burden, catheter-related injury, aging male populations, and broader use of minimally invasive urology procedures support demand.

What is the forecast growth rate for urethral dilators?

The category is forecast to grow at a 5.8% CAGR from 2027 to 2032, reaching USD 408.8 million in 2032.

Which product type leads urethral dilator sales?

Balloon Dilators led with 31.9% revenue share in 2026, while Hydraulic Urethral Dilators are forecast to grow at a 7.6% CAGR through 2032.

Why are drug-coated balloons important in urethral stricture care?

Five-year ROBUST I results reported 71.7% freedom from reintervention, supporting their use for selected recurrent strictures.

Which end-user setting is expanding fastest?

Home Care Settings are projected to grow at an 8.9% CAGR through 2032 as more patients manage long-term treatment outside hospitals.

Which region is growing fastest for urethral dilator products?

Asia-Pacific is projected to grow at a 6.5% CAGR through 2032, supported by aging populations and expanding urology capacity.

Page last updated on: